Deutsche Bank Rates Insulet (PODD) buy, $190 Price Target

Deutsche Bank maintains its buy rating for Insulet Corporation with a $190 price target, a 23.52% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 10:01 AM EDT · Updated Jun 26, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Deutsche Bank rated Insulet Corporation ($PODD) "buy" with a $190 price target on June 23, 2026.

Since the rating, $PODD is up 5.8% after 1 week, up 10.1% after 1 month and down 1.9% to date (from the $143.90 close on Jun 23, 2026).

PODD Insulet Corporation

$141.10 -50.13% year to date

Daily close · Oct 16, 2026

Key Points

Deutsche Bank reiterated its buy rating on Insulet Corporation (PODD) with a $190 price target on June 23, 2026.
Deutsche Bank's $190 price target implies 23.52% upside from Insulet Corporation's ($PODD) current $153.82 share price.
Insulet's stock traded near $138.97 on Tuesday, with a market cap of $9.63 billion and a P/E ratio of 32.4.
Insider transactions included both buys and sells, while analysts like Truist and Citigroup also weighed in with ratings.

Get $PODD trade alerts by text

We text you when insiders, Congress or big funds trade $PODD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Insulet Corporation alert may contain errors. Disclosures

On June 23, 2026, Deutsche Bank reiterated its buy rating on Insulet Corporation (NasdaqGS: PODD), setting a price target of $190. This reaffirmation comes as Insulet's shares traded around $138.97 on Tuesday.

Analyst rating track record

Deutsche Bank vs. the S&P 500

YTD return +24.63% hypothetical

All-time return +56.10% S&P 500 +38.94%

vs. S&P 500 +17.16% ahead of the index

Hypothetical returns from Deutsche Bank's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Deutsche Bank's analyst Kieran Ryan maintained the buy rating on Insulet with a $190 price target. Earlier, Truist Securities also maintained a buy rating with a $219 target on June 12, 2026. Citigroup kept a hold rating with a $165 target on May 28, 2026. Other firms like BTIG, B of A Securities, and Canaccord Genuity have also maintained buy ratings with targets ranging from $208 to $249.

Other Institutional Activity in Insulet Corporation

In recent institutional movements, BlackRock, Inc. reduced its holdings by 202,944 shares, leaving it with 6,375,943 shares valued at approximately $1.34 billion. Meanwhile, Vanguard Capital Management LLC opened a new position with 4,579,274 shares worth about $960.9 million. FMR LLC decreased its stake by 2,350,642 shares, now holding 3,974,712 shares valued at $834.1 million. Vanguard Portfolio Management LLC also opened a new position, acquiring 3,449,987 shares worth roughly $723.9 million.

Insulet Corporation Stock Up 10.8%

Shares of Insulet Corporation traded near $138.97 on Tuesday. The company, with a market cap of around $9.63 billion, has a P/E ratio of 32.4 and a forward P/E of 17.2. Its beta is 1.125, indicating moderate volatility compared to the market. The stock's 52-week range spans from a low of $138.79 to a high of $354.88, with a 50-day moving average of $165.10 and a 200-day moving average of $256.42. Insulet has a current ratio of 2.49 and a debt-to-equity ratio of 77.84.

12-month forecast

$PODD price target

Insulet Corporation daily closes and this analyst's $190 target. Not advice.

Recent Earnings

In its recent earnings report, Insulet Corporation posted revenue of $2.90 billion, reflecting a growth rate of 33.9%. The company's net margin stood at 10.4%, with a return on equity of 23%. Earnings per share (EPS) were reported at $4.29. The next earnings announcement is expected on August 6, 2026.

Insider Buying and Selling at Insulet Corporation

Recent insider activity at Insulet Corporation saw Luciana Borio selling 418 shares at an average price of $143.27 on June 3, 2026. On the same day, Timothy Stonesifer and Elizabeth Weatherman each purchased shares, with Stonesifer buying 2,790 shares at $143.51 and Weatherman acquiring 3,450 shares at $144.20. Earlier, on May 20, 2026, insiders including Luciana Borio, Timothy Scannell, and Robert Luther Huffines each bought 1,660 shares, though no price was specified.

About Insulet Corporation

Insulet Corporation, headquartered in Acton, Massachusetts, specializes in the development and sale of innovative insulin delivery systems. Its flagship products, the Omnipod platform, include the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system. These devices use Bluetooth communication to integrate with glucose monitors. The company also collaborates with Amgen to supply pods for the Neulasta Onpro kit. Insulet, led by CEO Ashley A. McEvoy, employs around 5,400 people.

Bottom Line

Deutsche Bank's reaffirmation of its buy rating on Insulet Corporation, with a $190 price target, highlights ongoing confidence in the company's growth potential. Investors often track such analyst ratings for insights into future stock performance. It's important to remember that these ratings are based on past data and do not necessarily predict future outcomes.